Galecto, Inc. (GLTO) Research

Galecto, Inc. is a clinical-stage biotechnology company focused on creating new therapeutic agents for a range of illnesses, including fibrotic conditions, cancer, and inflammation. Its most advanced investigational drug, GB2064, is currently undergoing Phase IIa clinical studies to treat myelofibrosis. The company is also developing GB0139, an inhalable compound that targets galectin-3, which is in Phase IIb trials for severe fibrotic lung disorders, such as idiopathic pulmonary fibrosis (IPF)—a serious and progressively worsening lung disease. Additionally, Galecto is advancing GB1211, a selective oral galectin-3 inhibitor, with ongoing Phase IIa trials for cancer and Phase Ib/IIa trials for fibrosis. Founded in 2011, Galecto, Inc. is headquartered in Boston, Massachusetts.

Market snapshot

Symbol
GLTO
Price
$21.58
Day change
-3.36%
Market cap
$1.3B
P/E ratio
-0.12x
52-week range
2.01-38.325
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$43.67

Peer companies

  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Adial Pharmaceuticals, Inc. (ADIL)
  • Aprea Therapeutics, Inc. (APRE)
  • Aptevo Therapeutics Inc. (APVO)
  • BioCardia, Inc. (BCDA)
  • IN8bio, Inc. (INAB)
  • Kiora Pharmaceuticals, Inc. (KPRX)
  • Lyra Therapeutics, Inc. (LYRA)

Recent insider activity

  • Bruno Julianne — M-Exempt (129000 shares) on 2026-02-09
  • Bruno Julianne — M-Exempt (129 shares) on 2026-02-09
  • Fairmount Funds Management LLC — M-Exempt (5809000 shares) on 2026-02-09
  • Fairmount Funds Management LLC — M-Exempt (2904000 shares) on 2026-02-09
  • Fairmount Funds Management LLC — M-Exempt (5809 shares) on 2026-02-09

Open Galecto, Inc. (GLTO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.